We correlated the fold change of gene expression in our RNA-seq data with that of a previously published microarray study comparing CD34+ cells from CP-CML patients who either responded or did not respond to imatinib [27]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.